Stock Groups

U.S. FDA authorizes Merck’s at-home antiviral COVID-19 pill -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO: An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021.

(Reuters) -The U.S. Food and Drug Administration on Thursday authorized Merck & Co’s antiviral pill for COVID-19, after giving the go-ahead to a similar treatment from Pfizer Inc (NYSE:) one day earlier

In a trial with Ridgeback Biotherapeutics of Merck’s drug molnupiravir it was found to be able to lower hospitalizations as well as deaths in high-risk patients early in the disease.

This oral medication is approved by the agency for mild to moderate COVID-19 treatment in adults at high risk of severe diseases and who have no other COVID-19 options.

For $700 per course, the U.S. government can purchase as many as 5 Million Courses of the Drug.

According to the FDA, the drug cannot be used in children under 18 years of age because it may cause bone and cartilage loss.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, futures, indexes and Forex. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts, buy/sell signal, and quotes. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]